Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Cytarabine/Mitoxantrone and Autotransplant for t-MDS/t-AML
NCT00774046Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Dec 2002
- Primary completion
- Mar 2011
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by University of Chicago. Started Dec 2002; status: completed.
02
Drugs
cytarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00774046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774046.